While the pharmacologic actions of CT have been studied extensively, there is a marked uncertainty about its role in mammalian physiology 11, 12 . This is primarily based on the fact that patients with CT-deficiency following thyroidectomy do not display the expected osteoporosis, and that bone mineral density was found decreased in individuals with medullary thyroid carcinoma 10, 13 . In addition, mice lacking Calca, the gene encoding CT and its related family member alpha calcitonin-gene-related peptide (αCGRP), unexpectedly displayed high bone mass, in contrast to mice specifically lacking αCGRP [14] [15] [16] . Importantly, although bone resorption was increased in aged Calca-deficient mice, there was a two-fold higher bone formation rate at all ages analyzed, suggesting that the primary physiological function of CT is to limit osteoblast activity. These findings did not only challenge our understanding of CT as a bone-preserving hormone, they also raised several questions of key significance. In addition, they suggested that understanding the cellular and molecular mode of CT action would help to identify novel osteoanabolic treatment options.
To study the impact of CT on skeletal integrity, we generated a mouse model allowing celltype specific deletion of two Calcr exons encoding the CT-binding site of the CTR. Here we show that CTR inactivation in all cell types or in osteoclasts specifically causes increased bone formation. The indirect influence of CT on bone formation is molecularly explained by a CTR-mediated inhibition of Spns2 expression, encoding a transporter for sphingosine 1-phosphate (S1P), one of the previously identified molecules potentially coupling bone formation to bone resorption 17, 18 . Likewise, S1P levels are increased in bones of CTRdeficient mice, and their skeletal phenotype is normalized by additional absence of S1P 3 , a S1P receptor expressed by osteoblasts.
Results

Inactivation of the CTR specifically affects bone formation
To understand the mechanism of CT action on bone remodeling, we generated a floxed allele of the CTR by homologous recombination in embryonic stem cells. As it was reported that deletion of exons 6 and 7 from the Calcr gene causes embryonic lethality 19 , we constructed a targeting vector resulting in the insertion of loxP sites 5′ of exon 6 and 3′ of exon 7, respectively ( Supplementary Fig. 1a ). After confirming homologous recombination by Southern Blotting (Supplementary Fig. 1b) , we removed the neomycin resistance cassette by Flp-mediated recombination and injected embryonic stem cells carrying one floxed Calcr allele into blastocysts to generate heterozygous mice. These were first mated with CMV-Cre transgenic mice 20 , leading to the generation of mice carrying a recombined Calcr allele, independent of Cre expression. The subsequent mating of Calcr +/− mice resulted in wildtype, heterozygous and Calcr-deficient animals, which were born at the expected Mendelian ratio ( Supplementary Fig. 1c,d ). Since this result did not confirm the embryonic lethality of Calcr-deficient mice observed by others 19 , it was important to demonstrate loss of a functional CTR in our model. Immunohistochemistry confirmed the absence of the CTR protein in kidney and hypothalamus sections from Calcr −/− mice (Fig. 1a) , and binding assays employing iodinated CT demonstrated the lack of specific binding to cultured Calcr −/− osteoclasts (Fig. 1b) . In addition, CT inhibited the resorptive activity of wildtype, but not of Calcr −/− osteoclasts, when these cells were cultured on dentin chips for 10 days (Fig. 1c) .
After backcrossing the mutant allele into the C57Bl/6 genetic background we analyzed 12 weeks old wildtype and Calcr −/− littermates for potential phenotypic abnormalities. Determination of blood parameters demonstrated no alterations in mineral homeostasis (Supplementary Table 1 ) and ruled out the existence of hepatic (Supplementary Table 2 ) and renal defects (Supplementary Table 3) in Calcr −/− mice, which was confirmed by histology ( Supplementary Fig. 1e ). Importantly, Calcr −/− mice displayed higher circulating levels of alkaline phosphatase, suggesting increased bone formation as an underlying cause. Therefore, we went on to analyze the skeletal phenotype of Calcr −/− mice using nondecalcified histology followed by static and dynamic histomorphometry. Here we observed an increased trabecular bone mass compared to wildtype littermates, which was solely explained by increased bone formation (Fig. 1d,e) . Since osteoporosis is most common in aged individuals, we next assessed the skeletal phenotype of Calcr −/− mice at 6, 12 and 18 months of age. Compared to wildtype littermates Calcr −/− mice displayed an increased trabecular bone mass together with an elevated bone formation rate at all ages analyzed (Fig.  1f) . In contrast, bone resorption was not increased in Calcr −/− mice, representing an unexpected finding as our previous analysis of aged CT-deficient mice revealed a high bone turnover phenotype with a more than two-fold increase in bone resorption markers 15 .
To confirm this striking difference between the two models we applied μCT-scanning and determined porosity of the femoral cortex (Fig. 2a ) and calvarial bone (Fig. 2b ) in 18 months old mice. While only a moderate difference between wildtype and Calcr −/− mice could be detected, we found severe cortical and calvarial porosity in CT-deficient Calca −/− mice that were maintained on the same genetic background. Since αCGRP −/− mice did not display this phenotype either, we hypothesized that the observed differences between Calcr −/− and Calca −/− mice are explained by the fact that the latter ones additionally lack procalcitonin (PCT), a well-established sepsis biomarker, which has been shown to interact with receptor complexes other than CT 6, 21 . To address this possibility we injected lipopolysaccharide (LPS) onto the calvaria of 6 weeks old wildtype, Calcr −/− , Calca −/− and αCGRP −/− mice and applied μCT-scanning one week thereafter (Fig. 2c) . As expected, LPS treatment led to a significant increase in calvarial porosity in mice of all genotypes, yet its effect was significantly more pronounced in Calca −/− mice. At the histological level these differences were explained by increased osteoclastogenesis (Fig. 2d) , which led us to analyze the effect of PCT on osteoclast formation ex vivo. Here we found that the number of TRAP-positive multinucleated osteoclasts was significantly reduced by PCT, and most importantly the same was the case in Calcr −/− cultures (Fig. 2e) . Collectively, these findings do not only suggest that PCT can affect bone mass in a CTR-dependent manner, they also demonstrated that the major physiological function of the CTR is to limit the activity of osteoblasts.
The CTR in osteoclasts controls bone formation
To identify the relevant expression site mediating the inhibitory influence of the CTR on bone formation, we crossed Calcr fl/fl mice with transgenic mice expressing the Cre recombinase either in osteoblasts (Runx2-Cre), in the hypothalamus (CamK2a-Cre) or in the osteoclast lineage (Lysm-Cre) [22] [23] [24] . The specificity of the chosen approach was confirmed by genomic PCR amplifying the recombined allele from different tissues and bone cells ( Supplementary Fig. 2a ). In addition, we performed immunohistochemistry on hypothalamus sections (Fig. 3a) and binding assays with cultured osteoclasts (Fig. 3b) , demonstrating that Calcr fl/fl mice carrying the CamK2a-Cre transgene lacked the CTR only in the hypothalamus, whereas binding of iodinated CT was decreased only in osteoclasts derived from Calcr fl/fl mice carrying the Lysm-Cre transgene. We next analyzed the skeletal phenotype of the corresponding mice at 6 months ( Supplementary Fig. 2b ) and 12 months (Fig. 3b ) of age and found that the trabecular bone volume was increased only in Calcr fl/fl mice carrying the Lysm-Cre transgene. Consistent with the results from Calcr −/− mice, this phenotype was fully explained by increased bone formation, while bone resorption was not affected. These findings demonstrated that the inhibitory influence on bone formation is mediated by the CTR in osteoclasts, which led us to study the underlying molecular mechanisms by cell culture experiments.
CT negatively regulates S1P release from osteoclasts
We first confirmed the absence of an endogenous defect of CTR-deficient bone marrow cells in terms of osteoclast differentiation, as suggested by the previous data ( Fig. 1c and Fig. 2e ). More specifically, we monitored expression of two key regulators of osteoclastogenesis, Nfatc1 and Fos, during the course of differentiation and found no difference between wildtype and Calcr −/− cultures (Fig. 4a ). Similar observations were made when the bone marrow cells were stimulated to differentiate into osteoblasts, where we did not observe differential expression of osteogenic markers, such as Alpl, Sp7 and Bglap (Fig. 4b) . We next isolated RNA from wildtype and Calcr −/− osteoclasts treated with CT for 6 hours to perform genome-wide expression analysis. This allowed us to identify at least 29 genes regulated by CT specifically in wildtype osteoclasts ( Supplementary Fig. 3a ). Our analysis revealed that the expression of well-established osteoclast markers, such as Tracp5 and Ctsk, was not affected by CT administration, while the expression of Calcr and Crem, the two previously known CT target genes in osteoclasts 25, 26 , was regulated as expected (Fig. 4c) . Most importantly, we identified Spns2 as a gene negatively regulated by CT specifically in wildtype osteoclasts. Spns2 encodes a transmembrane protein involved in the secretion of S1P 27, 28 , which has been shown to function as an osteoanabolic factor coupling bone formation to resorption in vitro 17, 18, 29 . Since this raised the possibility that the CTR-dependent control of bone formation is mediated by reducing S1P release from osteoclasts, and since other genes with a putative role in osteoclast to osteoblast communication (Sphk1, Bmp6, Efnb2 and Sema4d) were not differentially expressed, we focused on Spns2 as a relevant downstream target of CT in the control of bone formation.
Consistent with the suspected role of Spns2 in osteoclast to osteoblast communication, we observed that its expression increased during osteoclastogenesis of wildtype cells, in contrast to Sphk1 and Sphk2, the two genes required for intracellular S1P production (Fig.  4d) . Likewise, immunohistochemistry on human bone sections revealed that SPNS2 was readily detectable in multinucleated osteoclasts at the bone surface (Fig. 4e) . Consistent with the higher expression of Spns2 in differentiated osteoclasts we found that intracellular S1P levels declined during the course of osteoclastogenesis and that CT administration significantly increased them (Fig. 4f) . Likewise, qRT-PCR confirmed that Spns2 expression is negatively regulated by short-term administration of CT to wildtype osteoclasts, but not to Calcr −/− osteoclasts (Fig. 4g) . As it was previously demonstrated that protein kinase A (PKA), protein kinase C (PKC), and phospholipase C (PLC) are the major intracellular effectors of CTR-dependent signaling 25, 30, 31 , we investigated which of these pathways is involved in the transcriptional regulation of Spns2 by CT. Here we found that the inhibition of Spns2 expression by CT was abrogated in the presence of the PLC inhibitor U-73122, but not by a PKC or PKA inhibitor, indicating an involvement of the PLC-signaling pathway ( Supplementary Fig. 3b ). In addition, we found that Spns2 protein levels were markedly decreased after 9 hours of CT administration ( Supplementary Fig. 3c ), thereby supporting our conclusion that Spns2 is a direct target of CT in osteoclasts. To demonstrate the functional consequence of this regulation we determined S1P levels in the medium of wildtype and Calcr −/− osteoclast cultures. While in both wildtype and Calcr −/− osteoclast cultures extracellular S1P levels increased upon differentiation, CT administration for 24 hours resulted in a significant reduction only in wildtype cultures (Fig. 4h) . Taken together, these results suggested that the CTR controls bone formation by reducing S1P release from osteoclasts, which led us to address the question which of the five known S1P receptors 32, 33 is involved in the regulation of bone formation downstream of CT.
Control of bone formation by S1P 3 We next determined the expression of S1pr1-5 in different tissues as well as in primary bone cells by RT-PCR ( Supplementary Fig. 4a ) and during the course of their differentiation by qRT-PCR (Fig. 5a ). Here we found that S1pr1 and S1pr3 were differentially expressed during osteoblastogenesis, both increasing at early stages of differentiation. Since S1pr1-deficient mice die in utero 34 , in contrast to S1pr3-deficient mice, which do not display obvious abnormalities 35 , we first analyzed the skeletal phenotype of S1pr3-deficient mice. Our histomorphometric analysis revealed that bone remodeling parameters did not differ between wildtype and S1pr3-deficient mice at 3 months of age. In contrast, 8 months old S1pr3-deficient mice displayed osteopenia and reduced bone formation, while bone resorption parameters were unaffected (Fig. 5b) . We additionally generated mice lacking S1pr1 specifically in osteoblasts, but here we failed to detect alterations in bone mass or bone remodeling parameters at both ages ( Supplementary Fig. 4b-d) . These findings identified S1P 3 , encoded by the S1pr3 gene, as a candidate receptor controlling bone formation in response to S1P, which led us to utilize the S1pr3-deficient mouse model for additional experiments.
Here we first cultured primary calvarial osteoblasts from wildtype and S1pr3 −/− mice in the presence of conditioned medium derived from osteoclast progenitors or from osteoclasts terminally differentiated with or without CT. After 10 days of culture we quantified matrix mineralization and found that only conditioned medium of osteoclasts cultured without CT caused on osteoanabolic effect in wildtype cultures, whereas S1pr3 −/− cells did not respond (Fig. 5c ). Likewise, S1P significantly increased matrix mineralization in wildtype, but not in S1pr3 −/− bone marrow-derived osteoblast cultures (Fig. 5d) . Moreover, S1P treatment resulted in a rapid phosphorylation Erk1/2 in primary calvarial osteoblasts form wildtype, but not from S1pr3 −/− mice (Fig. 5e, Supplementary Fig. 5 ). To analyze immediate effects on gene expression we treated wildtype and S1pr3 −/− bone marrow cells at day 10 of osteogenic differentiation with S1P for 6 hours and subsequently performed qRT-PCR for selected genes (Fig. 6a) . Similar to the effect of CT on Calcr expression in osteoclasts, S1P negatively regulated S1pr3 expression in wildtype cultures. Importantly, short-term S1P administration caused an S1P 3 -dependent increase in the expression of Col1a1, Ibsp, and Smpd3, all of which are involved in bone matrix production by osteoblasts [36] [37] [38] , and addition of the MEK1 inhibitor PD98059 blunted the stimulatory effect of S1P on Col1a1 expression (Fig. 6b) . Taken together, these results suggested that S1P 3 is one relevant receptor acting downstream of CT to control bone formation.
Since S1P has been shown to induce expression of the pro-osteoclastogenic cytokine Rankl in osteoblasts, we additionally performed qRT-PCR to assess transcription of the genes encoding Rankl (Tnfsf11) or its decoy receptor Opg (Tnfrsf11b). While Tnfsf11 expression was induced by S1P stimulation of wildtype and S1pr3 −/− bone marrow cells, Tnfrsf11b was not affected (Fig. 6c) . These results raised the question, why the suspected increase of S1P release in Calcr −/− mice does not amplify osteoclastogenesis. In an attempt to address this question, we took advantage of Sgpl1 −/− mice, lacking S1P-lyase, an enzyme required for S1P degradation 39 . Due to high extracellular S1P levels, Sgpl1 −/− mice display various abnormalities and reduced life span (29 days in average). Remarkably, however, their bone mass was progressively increasing and approximately doubled compared to wildtype littermates in all animals reaching the age of 6 weeks ( Fig. 6d,e) . Of note, TRAP activity staining combined with cellular histomorphometry demonstrated increased osteoclastogenesis in Sgpl1 −/− mice (Fig. 6f) . Importantly, these osteoclasts were functionally active, as the serum crosslaps concentrations were significantly increased, and the same was the case for PICP, a biomarker of bone formation (Fig. 6g ). These findings fully confirm the osteoanabolic function of S1P in vivo and suggest that an S1P-driven high bone turnover is only detectable when the extracellular S1P level exceed a certain threshold.
S1pr3-deficiency abrogates osteoanabolic influences
To analyze if S1P is responsible for the high bone mass phenotype of Calcr −/− mice, we determined S1P levels in serum and bones of 6 months old wildtype and Calcr −/− littermates. Here we did not identify differences in circulating S1P levels, yet S1P concentrations were significantly increased in femur and spine extracts of Calcr −/− mice, and the same was the case in Calca −/− mice (Fig. 7a) . We next generated mice lacking both, the CTR and S1P 3 , and compared their skeletal phenotype to wildtype, Calcr −/− and S1pr3 −/− controls at 4 months of age. Here we observed the expected increase of trabecular bone mass and bone formation in Calcr −/− mice, yet this phenotype was not present in Calcr −/− mice additionally lacking deletion of S1P 3 (Fig. 7b ). Since it was described that daily injection of the non-selective S1P receptor agonist FTY720 protects against ovariectomy-induced bone loss in wildtype mice 40 , we further investigated whether this effect is attributable to a S1P 3 -dependent increase in bone formation. Therefore, we analyzed the skeletal phenotype of wildtype and S1pr3 −/− mice that received daily vehicle or FTY720 injections for 4 weeks, starting at the age of 3 months. FTY720 administration at a dose of 6 mg/kg resulted in a significantly increased trabecular bone volume in wildtype mice, while S1pr3 −/− mice did not respond (Fig. 7c) . Most importantly, while osteoclast parameters were not different in the six groups of mice, the bone formation rate was significantly increased by FTY720 administration in wildtype, but not S1pr3 −/− mice.
Since these results suggested that S1P 3 might be an attractive target for osteoanabolic therapy, we further assessed, whether its presence on osteoblasts is also detectable in human bone sections. Using immunohistochemistry we found that S1P 3 was detectable not only in spine sections from wildtype mice, but also in iliac crest biopsy sections from an individual with Paget's disease of bone, a condition characterized by a local increase of bone remodeling (Fig. 7d) . Taken together, our findings provide a cellular and molecular explanation for the role of CT in mammalian physiology and identify a physiologically relevant coupling mechanism in bone remodeling that can be targeted for osteoanabolic treatment of bone loss disorders (Fig. 7e ).
Discussion
Our results have identified a cellular and molecular explanation for the previously ambiguous role of CT in mammalian physiology. They demonstrate that bone formation is controlled by the CTR in osteoclasts, where CT reduces S1P secretion by inhibiting Spns2 expression. In turn, the high bone mass phenotype in mice lacking the CTR is the consequence of locally increased S1P levels, which is best underscored by the phenotypic rescue through additional deletion of S1P 3 . These findings are important and clinically relevant for several reasons. First, they demonstrate that the primary physiological function of mammalian CT in bone remodeling is entirely different from its pharmacologic action, similar to PTH, a hormone physiologically activating osteoclastogenesis, but pharmacologically increasing bone formation 41 . Second, they fully support the previously suggested role of S1P as a factor coupling bone formation to bone resorption, which was based on in vitro-and ex vivo-evidence 17, 18, 29 . Third, they have identified two promising target molecules for an osteoanabolic treatment of bone loss disorders, and it is important to state that the CTR and S1P 3 are both serpentine receptors, representing the major class of target proteins for drug development 32, 33, 42 .
Since CT was initially identified as a potent inhibitor of bone resorption at high pharmacological doses, it has long been considered as surprising that thyroidectomy does not cause osteopenia, and that bone mineral density is even decreased in individuals with medullary thyroid carcinoma (MTC) 12 . During the course of our study we identified three patients with CT-deficiency due to thyroiditis, and three patients with high CT serum levels due to MTC (Supplementary Table 4 ). Dual-energy x-ray absorptiometry (DEXA) revealed high bone mineral density in patients with CT-deficiency, whereas the opposite was observed in patients with CT-excess ( Supplementary Fig. 6a,b) . We additionally recruited 17 previously thyroidectomized individuals (Supplementary Table 5 ) to perform DEXA analyses, where we observed a significant positive correlation between bone mineral density and time after thyroidectomy ( Supplementary Fig. 6c ). These findings, despite several limitations of our analysis, are principally in agreement with the data obtained in mouse models, and they provide further evidence for a physiological role of mammalian CT as an inhibitor of bone formation. At that point it is again important to state that many conclusions regarding the functions of CT are based on experiments performed with salmon CT. This protein shares only 50 % sequence homology to human CT, which may not only translate into different binding characteristics to the CTR, but also in differential effects on bone remodeling. Therefore, our findings do not at all question the anti-resorptive effect of pharmacological salmon CT administration, they only show that mammalian CT has another influence under physiological conditions. We and others have previously shown that mice lacking CT or one allele of the CTR display increased bone formation 14, 15, 19 . Albeit these data already suggested that the primary physiological function of CT is different from its pharmacologic effect, there were still several remaining questions 43 . In fact, while the homozygous deletion of exons 6 and 7 of the Calcr gene, which encode the CTR binding site, has been reported to cause embryonic lethality 19 , a CMV-Cre mediated deletion of the 3′-Calcr exons 13 and 14 did not result in embryonic lethality or obvious alterations of bone remodeling, which was potentially explained by insufficient recombination 44 . Based on these inconsistencies it was important that we could demonstrate loss of CTR expression and function in our mouse model by several means, and that we could identify increased bone formation as their only phenotype. Although we do not have a sufficient explanation for the previously described lethality of mice lacking the Calcr exons 6 and 7, it is important to state that one difference between the two targeting strategies is the absence or presence of the Neo R cassette. In fact, since there are several reports demonstrating a phenotypic influence of such an insertion [45] [46] [47] , we have applied Flp-mediated recombination to remove the Neo R cassette before our phenotypic analysis. Our data clearly demonstrated that the major physiological function of the murine CTR is to limit bone formation, which led us to address the remaining questions about the underlying cellular and molecular mechanism.
Since the CTR is known to be present on hypothalamic neurons and differentiated osteoclasts, and since recent evidence has suggested that it might also be expressed by terminally differentiated osteoblasts 48 , we specifically deleted the Calcr exons 6 and 7 in the hypothalamus, in osteoblasts, or in cells of the osteoclast lineage to uncover the cellular and molecular mechanism explaining the inhibitory effect of CT on bone formation. The subsequent skeletal analysis demonstrated that the presence of the CTR in osteoclasts is required for regulating the activity of osteoblasts, thereby contradicting the hypothesis raised by us and others that CT inhibits bone formation through a hypothalamic relay 10, 19, 43 . Instead, our data demonstrate that CT and the CTR are involved in the molecular crosstalk between osteoclasts and osteoblasts. Clinically, there are several bone remodeling disorders where increased bone formation is triggered by excessive osteoclastogenesis, the most evident example being Paget's disease of bone [49] [50] [51] [52] . Molecularly, several tissue culture experiments together with genetic evidence from mouse models have led to the identification of candidate molecules mediating this function, such as EphrinB2, BMP6, Sema4d or S1P 17, 18, 53, 54 .
In the light of this knowledge, we performed genome-wide expression analysis with the aim to identify a coupling factor-encoding gene being regulated in a CTR-dependent manner. Here we did not observe an immediate transcriptional regulation of theses genes by CT, and the same was the case for Sphk1. In the context of S1P this latter finding is particularly important, as differential Sphk1 expression during osteoclastogenesis was the first experimental evidence for S1P as a relevant coupling factor in bone remodeling 19 . Instead, we observed a CTR-dependent negative regulation of Spns2 expression, which was potentially important, since this gene encodes a transmembrane protein required for S1P release from various cell types 27, 28, 55 . Our qRT-PCR expression analysis revealed that Spns2 expression increases during osteoclastogenesis, similar to extracellular S1P levels. Likewise, short-term administration of CT to wildtype, but not to Calcr −/− osteoclasts, caused a significant reduction of both, Spns2 expression and extracellular S1P accumulation. Consistent with these in vitro experiments, Calcr −/− mice displayed increased S1P levels in bone extracts, and their skeletal phenotype was normalized by the additional absence of S1P 3 . Taken together, these results demonstrate that the indirect action of CT on bone formation is explained by locally increased S1P concentrations, thereby supporting the concept that S1P receptors serve an osteoanabolic function.
Although we cannot fully rule out a contribution of additional S1P receptors, our results demonstrate that S1P 3 is one relevant receptor required to promote bone formation in response to S1P. While the lack of a bone remodeling phenotype in 3 months old S1pr3-deficient mice is potentially explained by functional redundancy, most likely involving S1pr1 based on its differential expression in osteoblasts, it was evident that S1pr3-deficiency blunted the effects of S1P in vitro, but also in vivo in the context of CTR deficiency. From a therapeutic perspective, the finding that FTY720 causes an S1P 3 -dependent osteoanabolic effect is of particular interest, as this non-selective S1P receptor agonist has already been approved for the treatment of individuals with multiple sclerosis 56, 57 . In a previous study, FTY720 administration (3 mg/kg) was found to protect against ovariectomy-induced bone loss due to a negative effect on osteoclast attachment to the bone matrix 40 . Although we principally used the same strategy of FTY720 administration, it is important to clarify the three relevant modifications compared to this former experiment. First, since we only observed a trend, and not a significant increase of the trabecular bone volume by daily injection of FTY720 at a dose of 3 mg/kg, we repeated the experiment with a higher dose (6 mg/kg) to demonstrate an osteoanabolic effect in wildtype mice. Second, our analysis included dynamic histomorphometry, which enabled us to identify differential effects on bone formation caused by FTY720 administration. And third, since we applied the same strategy to S1pr3-deficient mice, we were able to show that the osteoanabolic effect of FTY720 administration is mediated through S1P 3 .
Although these results provide an important proof-of-principle for the therapeutic potential of S1P receptor stimulation in osteoporotic individuals, they do not directly translate into clinical applicability, since the dosage used for treatment of multiple sclerosis is much lower (up to 5 mg per day) as compared to the animal experiments. Importantly however, while it is unlikely that FTY720 itself could be applied for osteoanabolic treatment in humans, it might be a promising approach to develop selective S1P 3 agonists and to analyze their potential for osteoporosis therapy. The osteoanabolic potential of S1P and its remarkable influence on bone remodeling is probably best underscored by the phenotype of Sgpl1 −/− mice. These mice have been described to display high extracellular S1P levels causing various abnormalities and early postnatal lethality 39 . Moreover, a non-quantitative analysis of their skeletal phenotype demonstrated high bone mass, which was interpreted as osteopetrosis, i.e. osteoclast dysfunction. Our histomorphometric analysis confirmed that the trabecular bone mass is dramatically increased in all Sgpl1-deficient mice reaching the age of 6 weeks (approximately 15 %). Importantly however, the number of functionally active osteoclasts was significantly increased towards wildtype littermates, and the same was the case for serum PICP, indicating excessive bone formation. In conclusion, Sgpl1-deficient mice display high bone turnover triggering a progressive bone mass increase, which occurs despite the existence of various organ abnormalities. These findings are in full agreement with the suspected key role of S1P in bone remodeling and its ability to act as an osteoanabolic molecule. Therefore, our collective findings do not only expand our current understanding of bone remodeling, they also identify two serpentine receptors specifically regulating bone formation. Since serpentine receptors represent the major class of target proteins for currently available drugs, it is conceivable to speculate that the development of CTRspecific antagonists and/or S1pr3-specific agonists might be a promising approach to counteract bone loss in osteoporosis or other skeletal disorders.
Methods
Mouse models
To obtain Calcr fl/fl mice a targeting construct was generated, where we placed a Frtneomycin-Frt-loxP cassette (kindly provided by G. Schuetz, Heidelberg, Germany) 5′ of exon 6 and a single loxP site 3′of exon 7, the latter one being inserted by ET recombination according to standard protocols. The construct was electroporated into embryonic stem cells R1, which were then screened for homologous recombination by Southern blotting following DNA digestion by Hind III. After removal of the neomycin resistance gene by electroporating a Flp-recombinase expression plasmid (kindly provided by G. Schuetz, Heidelberg, Germany), the targeted embryonic stem cells were injected in C57Bl/6J blastocysts to generate chimeric mice, which were then crossed with C57Bl/6 mice to obtain offspring with one floxed Calcr allele. These mice were either crossed to obtain Calcr fl/fl mice or with CMV-Cre transgenic mice, resulting in an ubiquitous recombination within the Calcr allele, as determined by Southern blotting or PCR genotyping using two primers flanking the loxP-site between exons 7 and 8 (5′-TCC TGG GCT GCT GAG AAA GTA TC-3′ and 5′-ATG TGA TTG GCT GGG CAC TG-3′) and one primer located 5′of the loxP site between exons 5 and 6 (5′-AAG ACA GAT GGT GAG GGC TGA CTG-3′). The generation and genotyping of Calca −/− , αCGRP −/− , S1pr1 fl/fl , S1pr3 −/− and Sgpl1 −/− mice has been described previously 14, 34, 35, 39, 58 . The same applies for mice expressing the Cre recombinase under the control of different promoters [22] [23] [24] . For the confirmation of cell-type specific S1pr1 inactivation, a combination of primers (5′-GAG CGG AGG AAG TTA AAA GTG-3′, 5′-CCT CCT AAG AGA TTG CAG CAA-3′ and 5′-GAT CCT AAG GCA ATG TCC TAG AAT GGG ACA-3′) amplifying either the floxed or the recombined allele. To rule out a possible influence of genetic background, all in vivo analyses were performed with littermate controls. While our initial analysis of the Calcr −/− phenotype was done with 12 weeks old male and female mice, we used female mice for subsequent analyses with ages ranging from 3 weeks until 18 months, as indicated in the respective figure legends. Animal care and experimental procedures were performed with approval from the animal care committees of the University Medical Center Hamburg-Eppendorf.
Immunological protein detection
Immunohistochemistry was performed according to standard protocols using polyclonal antibodies against the rat CTR (Acris), human SPNS2 (Lifespan), human S1P 3 (Lifespan) or mouse S1P 3 (Santa Cruz), all diluted 100-fold. Human bone sections were derived from decalcified iliac crest biopsies from an individual with M. Paget 52 , or from an autopsy case of a skeletal-intact donor. These studies were approved by the ethics committee of the Aerztekammer Hamburg. For immunohistochemistry the rehydrated sections were pretreated with 0.1% trypsin for 30 minutes, and then incubated in 3 % hydrogen peroxide for 15 minutes to block endogenous peroxidase activity. Incubation with 5 % BSA for 30 minutes was subsequently performed to block non-specific binding. Immunohistochemical staining with the primary antibodies was performed over night at 4°C. Detection was achieved with a biotinylated secondary goat anti-rabbit IgG (1:200, Dako Cytomation) followed by incubation with a streptavidin/HRP (1:200, Dako Cytomation). Peroxidase activity was detected using DAB as chromogenic substrate (Dako Cytomation). Sections were counterstained with hematoxylin, dehydrated, and mounted. For Western blotting whole cells were lysed RIPA buffer (1% NP-40, 1% sodium desoxycholate, 0.1% sodium dodecylsulfate, 150 mM sodium chloride, 2 mM EDTA, and 10 mM sodium phosphate) or in CHAPS extraction buffer (50 mM Tris/Hcl pH 8.0, 150mM NaCl, 5% glycerol, 1% CHAPS, 2mM EGTA, 1 mM DTT) containing a protease and phosphatase inhibitor cocktail (Roche). Equal amounts of protein were separated on 12.5 % SDS-PAGE and transferred to PVDF membranes (Hybond; GE Healthcare). After blocking with TBS containing 0.1% Tween 20 and 5% nonfat dry milk, membranes were incubated overnight at 4°C with primary antibodies at a dilution of 1:1000. The antibodies were directed against Spns2 (#ARP56057; Avia Systems Biology), β-actin (#MAB1501; Millipore), phospho-Erk1/2 (#9101; Cell Signaling Technology), or Erk1/2 (#4695; Cell Signaling Technology). Secondary HRP-conjugated antibodies (Dako) were used at a dilution of 1:5000.
Cell culture
Primary osteoclasts were generated as described previously 59 . In brief, osteoclast precursor cells were isolated from the bone marrow of 12 weeks old mice and differentiated for 4 days in α-MEM containing 10 nM 1,25(OH) 2 Vitamin D 3 . For the next 6 days they additionally received M-CSF (20 ng/ml) and RANKL (40 ng/ml) to allow terminal differentiation. The conditioned medium was collected from day 1-4 of culture (osteoclast precursor cells) or from day 7-10 of culture (mature osteoclasts). Primary osteoblasts were isolated by sequential collagenase digestion from the calvariae of 5 days old mice and differentiated for 10 days in the presence of 25 μg/ml ascorbic acid and 5 mM ß-glycerophosphate 59 . In some cases the culture medium contained 50 % of conditioned medium from osteoclast precursor cells or mature osteoclasts (cultured either in the absence or in the presence of 10 −7 M CT for the last 4 days) as indicated. To monitor effects of S1P on osteoblasts, bone marrow cells were differentiated for 10 days in the presence of 25 μg/ml ascorbic acid and 5 mM ß-glycerophosphate with or without S1P (1 μM). For short-term treatment cells were serumstarved over night and then stimulated with S1P (1 μM) for 6 hours.
Cellular assays
For binding assays mature osteoclasts were incubated for 2 hours with 10 −11 M 125 I-salmon CT in the absence or presence of 10 −8 M salmon CT. Bound radioactivity was released by 0.5 M NaOH and quantified in a γ-counter. For resorption assays bone marrow cells were plated on dentin slices and differentiated as described above (with CT added during the last 4 days). After staining with toluidine blue the resorbed area was quantified using ImageTool software. TRAP activity staining was performed as described previously 59 . In brief, after removal of the medium and two washing steps with PBS, cells were fixed with cold methanol for 5 minutes. After washing and drying they were stained with Naphtol ASMXPhosphate (Sigma) for 30 minutes, before the number of TRAP-positive multinuclear cells per well was determined. For pathway analyses osteoclasts were pre-incubated with inhibitors of PLC (U-73122, Sigma, #U6756; 10 μM), PKC (Chelerythrine chloride, Sigma, #C2932; 10 μM) or PKA (H-89, Sigma, #B1427; 300 nM) for 2 hours, followed by the stimulation with 10 −7 M CT for 6 hours. Likewise, osteoblasts were pre-treated with an Erk inhibitor (PD98059, Cell Signaling #9900, 50 μM) for 2 hours before stimulation with 10 −6 M S1P for 6 hours. For the assessment of matrix mineralization in primary osteoblast cultures, cells were stained after von Kossa, and the mineralized area was quantified using ImageTool software. For alizarin red staining, cells were incubated with 40 mM alizarin red staining solution (pH 4.2) for 10 minutes at room temperature after fixation in 90% ethanol. To quantify alizarin red incorporation cells were washed with PBS and fixed in 90% ethanol for 1 hour. After washing twice with distilled water, cells were stained with alizarin red S solution (40 mM, pH 4.2) for 10 minutes. Following additional washing steps with distilled water, the cell-bound alizarin red was dissolved in 10 % acetic acid. After incubation for 30 minutes at room temperature and 10 minutes at 85°C, the supernatant of a subsequent centrifugation step was neutralized with 10 % ammonium hydroxide solution, and the absorbance was measured at 405 nm.
Biochemical assays
Analysis of mineral homeostasis, kidney function, and determination of metabolic and hepatic parameters was carried out in the German Mouse Clinic as described 60 . All parameters were determined with a Beckman-Coulter AU 480 autoanalyzer, with the excecption of glycerol, which was measured using a kit from Randox Laboratories (Krefeld, Germnay). ELISA was used to measure concentrations of collagen degradation products (Crosslaps, IDS), Osteocalcin (Biomedical Technologies) and PICP (USCN Life Science). S1P concentrations were determined following HPLC analysis with all samples being collected in silicone-coated vessels 61 . The samples were transfered into siliconized glass tubes, internal standard was added and lipids were extracted by the addition of chloroform and methanol/HCl (99.8:0.2 v/v) after prior alkalization by 3N NaOH. The mixture was centrifuged (300 g, 5 min) to obtain the alkaline aqueous phase containing S1P. The organic phase was re-extracted with methanol, 1N NaCl and 3N NaOH. The combined aqueous phases were acidified by adding concentrated HCl and extracted twice with chloroform. The resulting organic phases were combined and evaporated by a vacuum system. The dried lipids were redissolved in methanol. Sample analyses were performed by rapid-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) using an Agilent 1200 Series binary pump, a degasser and an autosampler (Agilent Technologies, Böblingen, Germany). A quadrupole time-of-flight 6530 mass spectrometer (QTOF) equipped with JetStream technology operating in the positive electrospray ionization mode was used for detection (Agilent Technologies). High-purity nitrogen for the mass spectrometer was produced by a nitrogen generator (Parker Balston, Maidstone, UK). Chromatographic separations were obtained using a Waters X-Bridge C18 separation column (4.6 mm × 150 mm, 3.5 μm particle size, 138 Å pore size) with a Waters X-Bridge C18 guard column (4.6 × 20 mm; Waters). We chose a binary solvent system with gradient elution consisting of eluent A (water/formic acid; 100:0.1 v/v); and eluent B (acetonitril/tetrahydrofuran/formic acid; 50:50:0.1 v/v); and a flow rate of 0.5 ml/min over 15 minutes. Mass spectrometric measurements were conduct using the following ion source conditions and gas settings for positive LC-MS/MS: sheath gas temperature = 300°C; sheath gas flow = 9 l/min; nebulizer pressure = 30 psig; drying gas temperature = 300°C; drying gas flow = 8 l/min; capillary voltage = 5400 V; fragmentor voltage = 200 V; nozzle voltage = 2000 V; and collision energy = 15 V. Quantification was performed using MassHunter Software (Agilent Technologies). A calibration curve of analyte concentration was performed from 1-150 pmol and constructed by linear fitting using the least squares linear regression calculation. The resulting slope of the calibration curve was then used to calculate the concentration of the respective analyte in the unknowns.
Skeletal analysis
Before their skeletal analysis all mice were injected twice with calcein (30 mg / kg body weight) 9 and 2 days before sacrifice, which allowed a quantification of the bone formation rate by dynamic histomorphometry 62 . The dissected skeletons were fixed overnight in 4 % formalin and then transformed into 80 % ethanol, before an initial analysis by contact Xray was performed using a Faxitron Xray cabinet. The μCT scanning was performed using a Scanco μCT 40 apllying 55 kV, 145 μA and 200 ms integration time. Cortical bone was delineated and evaluated automatically using the image analysis algorithm provided by the manufacturer. The specific region for analysis of cortical thickness was a 1 mm thick section of the central diaphysis. Bone mineral density in patients, after obtaining informed consent, were measured in spine and both femora using dual-energy X-Ray absorptiometry (GE Lunar Prodigy DF+14622). In a subset of individuals structural bone parameters were determined in the left radius using high-resolution peripheral quantitative computed tomography (Scanco Medical xtremeCT). All blood parameters were determined by the Department of Clinical Chemistry. Exclusion criteria for the patient study were clinically apparent hypo-or hyperparathyroidism, Paget's disease of bone, impaired renal function, malignancies and metastatic bone disease, and bisphosphonate or teriparatide treatment.
Histology
Non-skeletal organs were histologically analyzed in the German Mouse Clinic as described 60 . All organs were fixed in 4 % buffered formalin, before being embedded into paraffin. Sections of 2 μm thickness were stained with hematoxylin and eosin according to standard protocols. For bone-specific analyses dissected skeletons were fixed in 3.7 % PBSbuffered formaldehyde for 18 hours and then transferred into 80 % ethanol. Vertebral bodies L1 to L4 were dehydrated in ascending alcohol concentrations, before they were embedded into methylmetacrylate. Sections of 4 μm thickness were cut in the sagittal plane using a Microtec rotation microtome. These were stained by von Kossa/van Gieson (for static hisotmorphometry) and toluidine blue (for cellular histomorphometry) staining procedures as described 62 . To determine the bone formation rate all mice were injected twice with calcein 9 and 2 days before sacrifice. Static, cellular and dynamic histomorphometry at trabecular bone surfaces was carried out according to the guidelines of the American Society for Bone and Mineral Research 63 using an OsteoMeasure system (Osteometrics Inc., USA). TRAP activity staining was performed on decalcified sections using napthol AS-MX phosphate (Sigma) and Fast Red Violet LB salt (Sigma) in 40 mM acetate buffer (pH5).
Mice treatment
For induction of calvarial porosity, anesthetized mice were injected with 10 mg/kg LPS (E. coli O111:B4) onto their calvariae subcutaneously. After 6 days mice were sacrificed and calvariae subjected to μCT analyses as described above. For quantification of the porosity the Axiovision software (Carl Zeiss) was used, while osteoclasts number was determined after TRAP activity staining as described above. Treatment of wildtype and S1pr3-deficient mice with FTY720 was performed in accordance to previous a study. 40 More specifically 3 months old mice received daily intraperitoneal injections of FTY720 (3 mg/kg or 6 mg/kg) or vehicle (PBS containing 5 % acidified DMSO and 30 % BSA). After 4 weeks of treatment, the mice were analyzed for their skeletal phenotype as described above.
Expression analysis
RNA was isolated using the RNeasyMini kit (Qiagen). For genome-wide expression analysis, 5 μg of RNA were used for first strand cDNA synthesis. For Gene Chip hybridization, the fragmented cRNA was incubated in hybridization solution at 45°C for 16 hours, before the Gene Chips (Affymetrix MG 430 2.0) were washed using the Affymetrix Fluidics Station 450. Microarrays were scanned with the Affymetrix Gene Chip Scanner 7G, and the signals were processed using GCOS(Affymetrix). The gene expression data have been deposited in GEO under accession code GSE60761. For RT-PCR expression analysis, 1μg of RNA was reversed transcribed using SuperScriptIII (Invitrogen) according to manufacturer′s instructions. Gene-specific primers were used to amplify fragments of S1pr1 (5′-GGC TTA TCT GGT CCC TCC TC-3′and 5′-CTT TGG CCT CAG CAA ATA GC-3′), S1pr2 (5′-CCC CCT TCC ATA AAC AAC CT-3′and 5′-CCC ATA CTG CCT CAC CTG AT-3′), S1pr3 (5′-TCT GCT TTC ACA CAA CAG CC-3′and 5′-GCA AGT AGC CAA GGT TGC TC-3′), S1pr4 (5′-GCA GAA GTC TCC ACG TCC TC-3′and 5′-GCT GAG TGA CCG AGA AGT CC-3′), S1pr5 (5′-TAT GGC TGC AGC AGA AAT TG-3′and 5′-TTC CTC TGT AGC CAG CCA CT-3′), and Gapdh (5′-GAC ATC AAG AAG GTG GTG AAG CAG-3′and 5′-CTC CTG TTA TTA TGG GGG TCT GG-3′), respectively. For qRT-PCR expression analysis, 1μg of RNA was reversed transcribed using SuperScriptIII (Invitrogen) according to manufacturer′s instructions. qRT-PCR analysis (with Gapdh as internal control) was performed using predesigned TaqMan gene expression assays (Applied Biosystems), with the exception of S1pr2, where qRT-PCR was performed using SYBR green (5'-CGC AGG CTG GAG CTT AGG GC-3' and 5'-GCA GGA GCT GGG TGA GCT GC-3').
Statistical analysis
The number of samples was chosen according to established standards providing sufficient statistical power to enable the detection of biologically relevant differences in animal models. Mouse data were analyzed by two-tailed Student′s t test using Excel software. All data are reported as mean ± SD. Human data were analyzed using IBM SPSS Statistics 20. p<0.05 was considered statistically significant.
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